Are oxidized low-density lipoprotein and C-reactive protein markers of atherosclerosis in nephrotic children?

Rybi-Szumińska, Agnieszka; Wasilewska, Anna; Michaluk-Skutnik, Joanna; Osipiuk-Remża, B.; Filonowicz, Renata; Zając, Magdalena

doi:10.1007/s11845-014-1170-8

Cited by 5 publications

(3 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…According to previous reports [ 37 , 38 , 39 , 40 ], the pathogeneses of NAFLD and atherosclerosis are both closely related to an imbalance of lipid metabolism. To explore the possible mechanism underlying the effectiveness of xyloketal B treatment of NAFLD, we investigated the effects of xyloketal B on lipid metabolism, mainly focusing on liver fatty acid synthesis and clearance pathways in vivo and in vitro.…”

Section: Discussionmentioning

confidence: 99%

Xyloketal B Attenuates Fatty Acid-Induced Lipid Accumulation via the SREBP-1c Pathway in NAFLD Models

et al. 2017

View full text Add to dashboard Cite

Abstract:The goal of this study was to examine the effects of xyloketal B on nonalcoholic fatty liver disease (NAFLD) and to explore the molecular mechanisms underlying its effects in both in vivo and in vitro models. We discovered an association between xyloketal B and the sterol regulatory element-binding protein-1c (SREBP-1c) signaling pathway, which is related to lipid metabolism. Mice were dosed with xyloketal B (5, 10 and 20 mg/kg/d) and atorvastatin (15 mg/kg/d) via intraperitoneal injection once daily for 40 days after being fed a high fat diet plus 10% high fructose liquid (HFD+HFL) for 8 weeks. Xyloketal B significantly improved HFD+HFL-induced hepatic histological lesions and attenuated lipid and glucose accumulation in the blood as well as lipid accumulation in the liver. Xyloketal B increased the expression of CPT1A, and decreased the expression of SREBP-1c and its downstream targeting enzymes such as ACC1, ACL, and FAS. Xyloketal B also significantly reduced lipid accumulation in HepG2 cells treated with free fatty acids (FFAs). These data suggested that xyloketal B has lipid-lowering effects via the SREBP-1c pathway that regulate lipid metabolism. Thus, targeting SREBP-1c activation with xyloketal B may be a promising novel approach for NAFLD treatment.

show abstract

Section: Discussionmentioning

confidence: 99%

Xyloketal B Attenuates Fatty Acid-Induced Lipid Accumulation via the SREBP-1c Pathway in NAFLD Models

et al. 2017

View full text Add to dashboard Cite

show abstract

“…Lipid disorders are not only acknowledged as one of the clinical characteristic of INS, but also known to be linked to disturbances in oxidative reactions and play an important role in the progression and complications of INS [ 7 ], especially high density lipoprotein cholesterol (HDL-C). HDL-C abnormalities in nephrotic syndrome impaired reverse cholesterol transport, contributed to endothelial dysfunction, oxidative stress, and systemic inflammation and consequently promoted atherosclerosis, and glomerulosclerosis [ 8 , 9 ], which further affected the renal prognosis of patients with INS.…”

Section: Introductionmentioning

confidence: 99%

Effect of high density lipoprotein cholesterol (HDL-C) on renal outcome in patients with nephrotic syndrome complicated with steroid-induced diabetes mellitus(SIDM)

Ding

Liu

et al. 2023

BMC Nephrol

View full text Add to dashboard Cite

Objective We aimed to investigate the renal prognosis of patients with idiopathic nephrotic syndrome (INS) complicated with steroid-induced diabetes mellitus (SIDM), the association of high-density lipoprotein cholesterol (HDL-C) before glucocorticoid treatment with renal prognosis, and the risk for persistent diabetes among patients with INS who had withdrawn from steroid therapy. Materials and methods We retrospectively analyzed 239 patients with INS complicated with SIDM at the National Clinical Research Center of Kidney Diseases, Jinling Hospital, from January 2008 to December 2019. The primary endpoint was the composite renal outcome defined as the development of end-stage renal disease (ESRD) or a 50% decrease in estimated glomerular filtration rate (eGFR) for more than 24 months after glucocorticoid withdrawal. The secondary endpoint was persistent diabetes, defined as fulfilling the criteria for diagnosing diabetes or using antidiabetic medications for at least 24 months after glucocorticoid withdrawal. Results After glucocorticoid withdrawal for over 24 months, 35 (14.6%) patients reached the composite renal endpoint: end-stage renal disease (n = 14) or a 50% decrease in eGFR (n = 21). Before glucocorticoid therapy, a level of HDL-C greater than 1.45 mmol/L worsened renal survival in patients with INS complicated with SIDM. The log10 the level of HDL-C before glucocorticoid treatment was an independent risk factor for the renal outcome. A prediction model was generated: Hazard ratio (renal outcome) = 0.94 * hypertension before glucocorticoid therapy + 2.29 * log10 level of HDL-C before glucocorticoid treatment + 0.90 * the grade of interstitial tubule injury (AUROC, 0.75; 95% CI, 0.63 to 0.87; P < 0.01). Meanwhile, a level of fasting plasma glucose (FPG) before glucocorticoid treatment greater than 5.2 mmol/L enhanced the likelihood of persistent diabetes for at least 24 months after glucocorticoid withdrawal. Conclusions Increased level of HDL-C before glucocorticoid therapy was independently associated with a higher risk for renal outcome and thus may be useful in the renal prognosis of patients with INS complicated with SIDM.

show abstract

“…Hyperlipidemia will trigger an increase in LDL levels to be converted to ox-LDL through activation of lipoxygenase and reactive oxygen species [8]. Previous studies have shown an increase in ox-LDL in pediatric nephrotic syndrome patients relative to control [9,10].…”

Section: Introductionmentioning

confidence: 99%

Combined supplementation with α-tocopherol and vitamin C improves the blood pressure of pediatric idiopathic nephrotic syndrome patients

Mellyana

Widajat

Sekarwana

2019

Clinical Nutrition Experimental

View full text Add to dashboard Cite

The purpose of the present study was to investigate the effects of combined supplementation with a-tocopherol and vitamin C on blood pressures and levels of ox-LDL and NOx in with pediatric idiopathic nephrotic syndrome patients. A total of thirty-six pediatric idiopathic nephrotic syndrome patients was involved in the study, which was assigned randomly into two groups, the control group of pediatric idiopathic nephrotic syndrome patients who received a standard therapy and placebo and the group of pediatric idiopathic nephrotic syndrome patients who received a standard therapy plus a-tocopherol and vitamin C. a-tocopherol and

show abstract

Are oxidized low-density lipoprotein and C-reactive protein markers of atherosclerosis in nephrotic children?

Cited by 5 publications

References 29 publications

Xyloketal B Attenuates Fatty Acid-Induced Lipid Accumulation via the SREBP-1c Pathway in NAFLD Models

Xyloketal B Attenuates Fatty Acid-Induced Lipid Accumulation via the SREBP-1c Pathway in NAFLD Models

Effect of high density lipoprotein cholesterol (HDL-C) on renal outcome in patients with nephrotic syndrome complicated with steroid-induced diabetes mellitus(SIDM)

Combined supplementation with α-tocopherol and vitamin C improves the blood pressure of pediatric idiopathic nephrotic syndrome patients

Contact Info

Product

Resources

About